AstraZeneca

History

Year	Detail
1913	AstraZeneca plc was founded in Sodertalje, Sweden, as an international pharmaceutical company engaged in the R&D, manufacturing, and marketing of pharmaceutical products.
1977	Tamoxifen, an ICI drug used for the treatment of breast cancer, was registered in the U.S.
1993	Imperial Chemical Industries (ICI) demerged its three business units and formed Zeneca Group PLC.
1999	Astra AB merged with Zeneca Group PLC to form AstraZeneca, one of the leading agrochemical and pharmaceutical companies. The merger's value was $67 billion.
2005-07	The company entered biotechnology by acquiring CAT, KuDOS, Medlmmune, and Arrow.
2014	AstraZeneca has acquired Almirall's respiratory division rights. This acquisition will provide AstraZeneca with ownership of rights for the development and commercialization of Almirall's proprietary respiratory business, such as revenues from the company's existing partnerships and its pipeline of investigational novel therapies.
2016	AstraZeneca has acquired Takeda Pharmaceutical's respiratory division. This acquisition includes expanding rights to roflumilast, the only approved oral PDE4 inhibitor for treating chronic obstructive pulmonary disease.
2021	AstraZeneca acquired Alexion Pharmaceuticals Inc., marking the company's entry into medicines for rare diseases and beginning a new chapter.